Thomas M Kaffenberger, Ryan J Soose, Patrick J Strollo, Olivier M Vanderveken
{"title":"Three-dimensional mean disease alleviation (3D-MDA): The next step in measuring sleep apnea treatment effectiveness.","authors":"Thomas M Kaffenberger, Ryan J Soose, Patrick J Strollo, Olivier M Vanderveken","doi":"10.1016/j.sleep.2024.11.027","DOIUrl":null,"url":null,"abstract":"<p><p>Mean disease alleviation measures the effectiveness of Obstructive Sleep Apnea (OSA) treatments. It combines a patient's adherence to treatment normalized to their total sleep time and the treatment's efficacy as determined by the change in the apnea-hypopnea index. This metric fails to capture the patient's OSA-related symptoms, which are a key component and, in some cases, the primary component, of determining response to treatment. We propose an enhanced metric called three-dimensional mean disease alleviation (3D-MDA), which incorporates the symptom response to better reflect the true treatment impact. RESULTS: The proposed 3D-MDA metric aims to provide a more comprehensive assessment of OSA treatment effectiveness by integrating the subjective impact, therapy adherence, and objective efficacy. Further, 3D-MDA is adaptable over time as the optimal metrics for these categories continue to evolve.</p>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"125 ","pages":"27-30"},"PeriodicalIF":3.8000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.sleep.2024.11.027","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Mean disease alleviation measures the effectiveness of Obstructive Sleep Apnea (OSA) treatments. It combines a patient's adherence to treatment normalized to their total sleep time and the treatment's efficacy as determined by the change in the apnea-hypopnea index. This metric fails to capture the patient's OSA-related symptoms, which are a key component and, in some cases, the primary component, of determining response to treatment. We propose an enhanced metric called three-dimensional mean disease alleviation (3D-MDA), which incorporates the symptom response to better reflect the true treatment impact. RESULTS: The proposed 3D-MDA metric aims to provide a more comprehensive assessment of OSA treatment effectiveness by integrating the subjective impact, therapy adherence, and objective efficacy. Further, 3D-MDA is adaptable over time as the optimal metrics for these categories continue to evolve.
平均疾病缓解率衡量阻塞性睡眠呼吸暂停（OSA）的治疗效果。它将患者的治疗依从性与他们的总睡眠时间和根据呼吸暂停-低通气指数的变化确定的治疗效果相结合。这一指标未能反映患者与 OSA 相关的症状，而这些症状是决定治疗反应的关键因素，在某些情况下甚至是主要因素。我们提出了一种名为三维平均疾病缓解率（3D-MDA）的增强型指标，它结合了症状反应，能更好地反映真实的治疗效果。结果：所提出的三维平均疾病缓解度量标准旨在通过整合主观影响、治疗依从性和客观疗效，对 OSA 治疗效果进行更全面的评估。此外，随着这些类别的最佳衡量标准不断发展，3D-MDA 也可随时间推移而调整。
期刊介绍：
Sleep Medicine aims to be a journal no one involved in clinical sleep medicine can do without.
A journal primarily focussing on the human aspects of sleep, integrating the various disciplines that are involved in sleep medicine: neurology, clinical neurophysiology, internal medicine (particularly pulmonology and cardiology), psychology, psychiatry, sleep technology, pediatrics, neurosurgery, otorhinolaryngology, and dentistry.
The journal publishes the following types of articles: Reviews (also intended as a way to bridge the gap between basic sleep research and clinical relevance); Original Research Articles; Full-length articles; Brief communications; Controversies; Case reports; Letters to the Editor; Journal search and commentaries; Book reviews; Meeting announcements; Listing of relevant organisations plus web sites.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
